Publikationen der KKE Neuropathologie

2017

Albrecht M, Stichel D, Muller B, Merkle R, Sticht C, Gretz N, Klingmuller U, Breuhahn K, Matthaus F: TTCA: an R package for the identification of differentially expressed genes in time course microarray data. BMC Bioinformatics 18 (1), 33, 2017.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A: Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol 133 (1), 1-3, 2017.

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD: The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133 (1), 5-12, 2017.

Sahm F, Korshunov A, Schrimpf D, Stichel D, Jones DT, Capper D, Koelsche C, Reuss D, Kratz A, Huang K, Wefers AK, Schick M, Bewerunge-Hudler M, Mittelbronn M, Platten M, Hanggi D, Jeibmann A, Unterberg A, Herold-Mende C, Pfister SM, Brandner S, Wick W, von Deimling A: Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathol 133 (2), 327-27, 2017.

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A: Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol Epub ahead of print.

Faria CC, Golbourn B, Dubuc AM, Remke M, Diaz RJ, Agnihotri S, Luck A, Sabha N, Olsen S, Wu X, Garzia L, Ramaswamy V, Mack SC, Wang X, Leadley M, Reynaud D, Ermini L, Post M, Northcott PA, Pfister SM, Croul S, Kool M, Korshunov A, Smith CA, Taylor MD, Rutka JT: Foretinib is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Res Epub ahead of print.

Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, Ouafik L, Scavarda D, Korshunov A, Jones DT, Figarella-Branger D: Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget Epub ahead of print.

Gunkel M, Chung I, Worz S, Deeg KI, Simon R, Sauter G, Jones DT, Korshunov A, Rohr K, Erfle H, Rippe K: Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods Epub ahead of print.

Johann PD, Hovestadt V, Thomas C, Jeibmann A, Hess K, Bens S, Oyen F, Hawkins C, Pierson CR, Aldape K, Kim SP, Widing E, Sumerauer D, Hauser P, van Landeghem F, Ryzhova M, Korshunov A, Capper D, Jones DT, Pfister SM, Schneppenheim R, Siebert R, Paulus W, Fruhwald MC, Kool M, Hasselblatt M: Cribriform neuroepithelial tumor: Molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathol Epub ahead of print.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A: cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol Epub ahead of print.

Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bachli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T: Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget Epub ahead of print.

Tzaridis T, Milde T, Pajtler KW, Bender S, Jones DT, Muller S, Wittmann A, Schlotter M, Kulozik AE, Lichter P, Collins VP, Witt O, Kool M, Korshunov A, Pfister SM, Witt H: Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget Epub ahead of print.

 

 

2016

Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J: Radiotherapy plus concomitant temozolomide in primary gliosarcoma. J Neurooncol 128 (2), 341-48, 2016.

Alexandrescu S, Korshunov A, Lai SH, Dabiri S, Patil S, Li R, Shih CS, Bonnin JM, Baker JA, Du E, Scharnhorst DW, Samuel D, Ellison DW, Perry A: Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas - Same Entity or First Cousins? Brain Pathol 26 (2), 215-23, 2016.

Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Kramer A, Heilig CE: Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. Leukemia 30 (4), 782-88, 2016.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R: Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17 (11), 1521-32, 2016.

Biller A, Badde S, Nagel A, Neumann JO, Wick W, Hertenstein A, Bendszus M, Sahm F, Benkhedah N, Kleesiek J: Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression. AJNR. American journal of neuroradiology 37 (1), 66-73, 2016. 

Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, Burke KA, Basili T, Li A, Geyer FC, Piscuoglio S, Ng CK, Jungbluth AA, Balss J, Pusch S, Baker GM, Cole KS, von Deimling A, Batten JM, Marotti JD, Soh HC, McCalip BL, Serrano J, Lim RS, Siziopikou KP, Lu S, Liu X, Hammour T, Brogi E, Snuderl M, Iafrate AJ, Reis-Filho JS, Schnitt SJ: IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Res 76 (24), 7118-29, 2016.

D'Asti E, Huang A, Kool M, Meehan B, Chan JA, Jabado N, Korshunov A, Pfister SM, Rak J: Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment. The American journal of pathology 186 (2), 446-59, 2016.

Ernst A, Jones DT, Maass KK, Rode A, Deeg KI, Jebaraj BM, Korshunov A, Hovestadt V, Tainsky MA, Pajtler KW, Bender S, Brabetz S, Grobner S, Kool M, Devens F, Edelmann J, Zhang C, Castelo-Branco P, Tabori U, Malkin D, Rippe K, Stilgenbauer S, Pfister SM, Zapatka M, Lichter P: Telomere dysfunction and chromothripsis. Int J Cancer 138 (12), 2905-14, 2016.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wunschel J, Pfeil S, Ercu M, Kunkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE: MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget 7 (41), 66344-59, 2016.

Gessi M, Capper D, Sahm F, Huang K, von Deimling A, Tippelt S, Fleischhack G, Scherbaum D, Alfer J, Juhnke BO, von Hoff K, Rutkowski S, Warmuth-Metz M, Chavez L, Pfister SM, Pietsch T, Jones DT, Sturm D: Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol 132 (4), 635-37, 2016.

Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M: EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17 (9), e383-91, 2016.

Grigaravicius P, Kaminska E, Hubner CA, McKinnon PJ, von Deimling A, Frappart PO: Rint1 inactivation triggers genomic instability, ER stress and autophagy inhibition in the brain. Cell death and differentiation 23 (3), 454-68, 2016.

Grigaravicius P, von Deimling A, Frappart PO: RINT1 functions as a multitasking protein at the crossroads between genomic stability, ER homeostasis, and autophagy. Autophagy 12 (8), 1413-15, 2016.

Hasselblatt M, Thomas C, Hovestadt V, Schrimpf D, Johann P, Bens S, Oyen F, Peetz-Dienhart S, Crede Y, Wefers A, Vogel H, Riemenschneider MJ, Antonelli M, Giangaspero F, Bernardo MC, Giannini C, Ud Din N, Perry A, Keyvani K, van Landeghem F, Sumerauer D, Hauser P, Capper D, Korshunov A, Jones DT, Pfister SM, Schneppenheim R, Siebert R, Fruhwald MC, Kool M: Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathol 132 (1), 149-51, 2016.

Heiland DH, Staszewski O, Hirsch M, Masalha W, Franco P, Grauvogel J, Capper D, Schrimpf D, Urbach H, Weyerbrock A: Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis. J Neuropathol Exp Neurol 75 (4), 358-65, 2016.

Heim S, Sill M, Jones DT, Vasiljevic A, Jouvet A, Fevre-Montange M, Wesseling P, Beschorner R, Mittelbronn M, Kohlhof P, Hovestadt V, Johann P, Kool M, Pajtler KW, Korshunov A, Ruland V, Sperveslage J, Thomas C, Witt H, von Deimling A, Paulus W, Pfister SM, Capper D, Hasselblatt M: Papillary tumor of the pineal region: A distinct molecular entity. Brain Pathol 26 (2), 199-205, 2016.

Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bahr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G: Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131 (2), 321-22, 2016.

Hoffmann A, Pfeil J, Alfonso J, Kurz FT, Sahm F, Heiland S, Monyer H, Bendszus M, Mueller AK, Helluy X, Pham M: Experimental Cerebral Malaria Spreads along the Rostral Migratory Stream. PLoS Pathog 12 (3), e1005470, 2016.

Hoffmann M, Koelsche C, Seiz-Rosenhagen M, Mai S, Lohr F, Reuss D, Wenz F, Gebhardt C, Giordano FA: The GNAQ in the haystack: intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman. J Neurosurg 125 (1), 53-6, 2016.

Holsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, Fahlbusch R, Metzler M, Kool M, Pfister SM, von Deimling A, Capper D, Jones DT, Buslei R: Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 4 (1), 20, 2016.

International Cancer Genome Consortium PedBrain Tumor P: Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nature medicine 22 (11), 1314-20, 2016.

Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Grobner S, Brabetz S, Chavez L, Bens S, Groschel S, Kratochwil F, Wittmann A, Sieber L, Georg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Schuller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Fruhwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM, Kool M: Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell 29 (3), 379-93, 2016.

Jungk C, Mock A, Exner J, Geisenberger C, Warta R, Capper D, Abdollahi A, Friauf S, Lahrmann B, Grabe N, Beckhove P, von Deimling A, Unterberg A, Herold-Mende C: Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Med 14 (1), 170, 2016.

Jungk C, Scherer M, Mock A, Capper D, Radbruch A, von Deimling A, Bendszus M, Herold-Mende C, Unterberg A: Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. J Neurooncol 129 (2), 803-20, 2016.

Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, Wick A, Eidel O, Schlemmer HP, Radbruch A, Debus J, Herold-Mende C, Unterberg A, Jones D, Pfister S, Wick W, von Deimling A, Bendszus M, Capper D: Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology 281 (3), 907-18, 2016.

Koelsche C, Renner M, Johann P, Leiss I, Sahm F, Schimmack S, Wardelmann E, Renker EK, Schirmacher P, Korshunov A, von Deimling A, Mechtersheimer G: Differential nuclear ATRX expression in sarcomas. Histopathology 68 (5), 738-45, 2016.

Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V, Sturm D, Meyer J, Jones C, Zheludkova O, Kumirova E, Golanov A, Kool M, Schuller U, Mittelbronn M, Hasselblatt M, Schittenhelm J, Reifenberger G, Herold-Mende C, Lichter P, von Deimling A, Pfister SM, Jones DT: Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 132 (1), 137-46, 2016.

Lemke D, Pledl HW, Zorn M, Jugold M, Green E, Blaes J, Low S, Hertenstein A, Ott M, Sahm F, Steffen AC, Weiler M, Winkler F, Platten M, Dong Z, Wick W: Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget 2016.

Li P, Lee EH, Du F, Gordon RE, Yuelling LW, Liu Y, Ng JM, Zhang H, Wu J, Korshunov A, Pfister SM, Curran T, Yang ZJ: Nestin Mediates Hedgehog Pathway Tumorigenesis. Cancer Res 76 (18), 5573-83, 2016.

Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, Haldipur P, Kawauchi D, Risch T, Warnatz HJ, Worst BC, Ju B, Orr BA, Zeid R, Polaski DR, Segura-Wang M, Waszak SM, Jones DT, Kool M, Hovestadt V, Buchhalter I, Sieber L, Johann P, Chavez L, Groschel S, Ryzhova M, Korshunov A, Chen W, Chizhikov VV, Millen KJ, Amstislavskiy V, Lehrach H, Yaspo ML, Eils R, Lichter P, Korbel JO, Pfister SM, Bradner JE, Northcott PA: Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530 (7588), 57-62, 2016.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6), 803-20, 2016.

Mangum R, Varga E, Boue DR, Capper D, Benesch M, Leonard J, Osorio DS, Pierson CR, Zumberge N, Sahm F, Schrimpf D, Pfister SM, Finlay JL: SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. Childs Nerv Syst 2016.

Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, Nied AK, Friauf S, Exner J, Capper D, Hartmann C, Lahrmann B, Grabe N, Debus J, von Deimling A, Popanda O, Plass C, Unterberg A, Abdollahi A, Schmezer P, Herold-Mende C: LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int J Cancer 139 (2), 341-48, 2016.

Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FM, Ramaswamy V, Lindsay PE, Jelveh S, Donovan LK, Wang X, Luu B, Zayne K, Li Y, Mayoh C, Thiessen N, Mercier E, Mungall KL, Ma Y, Tse K, Zeng T, Shumansky K, Roth AJ, Shah S, Farooq H, Kijima N, Holgado BL, Lee JJ, Matan-Lithwick S, Liu J, Mack SC, Manno A, Michealraj KA, Nor C, Peacock J, Qin L, Reimand J, Rolider A, Thompson YY, Wu X, Pugh T, Ally A, Bilenky M, Butterfield YS, Carlsen R, Cheng Y, Chuah E, Corbett RD, Dhalla N, He A, Lee D, Li HI, Long W, Mayo M, Plettner P, Qian JQ, Schein JE, Tam A, Wong T, Birol I, Zhao Y, Faria CC, Pimentel J, Nunes S, Shalaby T, Grotzer M, Pollack IF, Hamilton RL, Li XN, Bendel AE, Fults DW, Walter AW, Kumabe T, Tominaga T, Collins VP, Cho YJ, Hoffman C, Lyden D, Wisoff JH, Garvin JH, Stearns DS, Massimi L, Schuller U, Sterba J, Zitterbart K, Puget S, Ayrault O, Dunn SE, Tirapelli DP, Carlotti CG, Wheeler H, Hallahan AR, Ingram W, MacDonald TJ, Olson JJ, Van Meir EG, Lee JY, Wang KC, Kim SK, Cho BK, Pietsch T, Fleischhack G, Tippelt S, Ra YS, Bailey S, Lindsey JC, Clifford SC, Eberhart CG, Cooper MK, Packer RJ, Massimino M, Garre ML, Bartels U, Tabori U, Hawkins CE, Dirks P, Bouffet E, Rutka JT, Wechsler-Reya RJ, Weiss WA, Collier LS, Dupuy AJ, Korshunov A, Jones DT, Kool M, Northcott PA, Pfister SM, Largaespada DA, Mungall AJ, Moore RA, Jabado N, Bader GD, Jones SJ, Malkin D, Marra MA, Taylor MD: Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529 (7586), 351-7, 2016.

Neidert MC, Leske H, Burkhardt JK, Kollias SS, Capper D, Schrimpf D, Regli L, Rushing EJ: Synchronous pituitary adenoma and pituicytoma. Hum Pathol 47 (1), 138-43, 2016.

Neumann JE, Dorostkar MM, Korshunov A, Mawrin C, Koch A, Giese A, Schuller U: Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. J Neuropathol Exp Neurol 75 (5), 408-14, 2016.

Ochs K, Ott M, Rauschenbach KJ, Deumelandt K, Sahm F, Opitz CA, von Deimling A, Wick W, Platten M: Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. Journal of neurochemistry 136 (6), 1142-54, 2016.

Oh JE, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, Sure U, Vital A, Paulus W, Mittelbronn M, Antonelli M, Kleihues P, Giangaspero F, Ohgaki H: Genetic alterations in gliosarcoma and giant cell glioblastoma. Brain Pathol 26 (4), 517-22, 2016.

Oh JE, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, Sure U, Vital A, Paulus W, Mittelbronn M, Antonelli M, Kleihues P, Giangaspero F, Ohgaki H: Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. Brain Pathol 26 (4), 517-22, 2016.

Ploeger C, Waldburger N, Fraas A, Goeppert B, Pusch S, Breuhahn K, Wang XW, Schirmacher P, Roessler S: Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. Hepatology 64 (3), 828-42, 2016.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognar L, Klekner A, Hortobagyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tunon T, Schuller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD: Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol 34 (21), 2468-77, 2016. 

Reichenberger MA, Mueller W, Hartmann J, Diehm Y, Lass U, Koellensperger E, Leimer U, Germann G, Fischer S: ADSCs in a fibrin matrix enhance nerve regeneration after epineural suturing in a rat model. Microsurgery 36 (6), 491-500, 2016.

Rohrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT, Bewerunge-Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, Perry A, Mautner VF, Mechtersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hanggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss DE: Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol 131 (6), 877-87, 2016.

Sahm F, Jakobiec FA, Meyer J, Schrimpf D, Eberhart CG, Hovestadt V, Capper D, Lambo S, Ryzhova M, Schuller U, Zheludkova O, Kumirova E, Lichter P, von Deimling A, Jones DT, Pfister SM, Kool M, Korshunov A: Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. Genes Chromosomes Cancer 55 (5), 418-27, 2016.

Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schuller U, Jungk C, Wick A, Witt O, Platten M, Herold-Mende C, Unterberg A, Pfister SM, Wick W, von Deimling A: Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol 131 (6), 903-10, 2016.

Schiefer AI, Parlow L, Gabler L, Mesteri I, Koperek O, von Deimling A, Streubel B, Preusser M, Lehmann A, Kellner U, Pauwels P, Lambin S, Dietel M, Hummel M, Klauschen F, Birner P, Mobs M: Multicenter Evaluation of a Novel, Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn 18 (3), 370-77, 2016.

Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiss EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W: Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget 7 (50), 82028-45, 2016.

Schmidt M, Mock A, Jungk C, Sahm F, Ull AT, Warta R, Lamszus K, Gousias K, Ketter R, Roesch S, Rapp C, Schefzyk S, Urbschat S, Lahrmann B, Kessler AF, Lohr M, Senft C, Grabe N, Reuss D, Beckhove P, Westphal M, von Deimling A, Unterberg A, Simon M, Herold-Mende C: Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget 7 (12), 14551-68, 2016.

Seidel P, Remus M, Delacher M, Grigaravicius P, Reuss DE, Frappart L, von Deimling A, Feueuer M, Abdollahi A, Frappart PO: Epidermal Nbn deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. Oncotarget 7 (17), 23006-16, 2016.

Selt F, Deiss A, Korshunov A, Capper D, Witt H, van Tilburg CM, Jones DT, Witt R, Sahm F, Reuss D, Kolsche C, Ecker J, Oehme I, Hielscher T, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T: Pediatric targeted therapy: Clinical feasibility of personalized diagnostics in children with relapsed and progressive tumors. Brain Pathol 26 (4), 506-16, 2016.

Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Lastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lotsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Fruhwald MC, Milde T, Hasselblatt M, Wesseling P, Rossler J, Schuller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M: New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164 (5), 1060-72, 2016.

Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, Rosen G, Cancer M, Hutter S, Sundstrom A, Kawauchi D, Jones DT, Spruck C, Taylor MD, Cho YJ, Pfister SM, Kool M, Korshunov A, Swartling FJ, Sangfelt O: FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J 35 (20), 2192-212, 2016.

Thomas C, Sill M, Ruland V, Witten A, Hartung S, Kordes U, Jeibmann A, Beschorner R, Keyvani K, Bergmann M, Mittelbronn M, Pietsch T, Felsberg J, Monoranu CM, Varlet P, Hauser P, Olar A, Grundy RG, Wolff JE, Korshunov A, Jones DT, Bewerunge-Hudler M, Hovestadt V, von Deimling A, Pfister SM, Paulus W, Capper D, Hasselblatt M: Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro Oncol 18 (6), 790-96, 2016.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, Giannini C, Li KK, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DC, Seow WT, Chang KT, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fevre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobagyi T, Klekner A, Laszlo B, Pocza T, Hauser P, Schuller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen ML, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, Lopez-Aguilar E, Lyden D, Garzia L, Shih DJ, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DT, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD: Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17 (4), 484-95, 2016.

van Lith SA, Navis AC, Lenting K, Verrijp K, Schepens JT, Hendriks WJ, Schubert NA, Venselaar H, Wevers RA, van Rooij A, Wesseling P, Molenaar RJ, van Noorden CJ, Pusch S, Tops B, Leenders WP: Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Scientific reports 6 30486, 2016.

Voelxen NF, Walenta S, Proescholdt M, Dettmer K, Pusch S, Mueller-Klieser W: Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique. Frontiers in oncology 6 46, 2016.

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M, Neurooncology Working Group of the German Cancer S: Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 18 (11), 1529-37, 2016.

Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jurgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wossmann W, Nathrath M, Bielack SS, Fruhwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O: Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer 65 91-101, 2016.

 

2015

Adeberg S, Bernhardt D, Harrabi SB, Bostel T, Mohr A, Koelsche C, Diehl C, Rieken S, Debus J: Metformin influences progression in diabetic glioblastoma patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 191 (12), 928-35, 2015.

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A: Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129 (6), 829-48, 2015.

Antonelli M, Korshunov A, Mastronuzzi A, Diomedi Camassei F, Carai A, Colafati GS, Pfister SM, Kool M, Giangaspero F: Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. Virchows Archiv : an international journal of pathology 466 (5), 603-7, 2015.

Blank AE, Baumgarten P, Zeiner P, Zachskorn C, Loffler C, Schittenhelm J, Czupalla CJ, Capper D, Plate KH, Harter PN, Mittelbronn M: Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) is up-regulated in reactive astrocytes in human gliomas. Neuropathol Appl Neurobiol 141 (6), 1131-37, 2015.

Blank AE, Baumgarten P, Zeiner P, Zachskorn C, Loffler C, Schittenhelm J, Czupalla CJ, Capper D, Plate KH, Harter PN, Mittelbronn M: Tumour necrosis factor receptor superfamily member 9 (TNFRSF9) is up-regulated in reactive astrocytes in human gliomas. Neuropathol Appl Neurobiol 41 (2), e56-67, 2015.

Brandner S, von Deimling A: Review: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol 41 (6), 694-720, 2015.

Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M: Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest 125 (2), 593-606, 2015.

Campos B, Weisang S, Osswald F, Ali R, Sedlmeier G, Bageritz J, Mallm JP, Hartmann C, von Deimling A, Popanda O, Goidts V, Plass C, Unterberg A, Schmezer P, Burhenne J, Herold-Mende C: Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia 63 (10), 1850-59, 2015.

Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Jr., Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Jr., Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J: Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England journal of medicine 372 (26), 2481-98, 2015.

Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A, Sabbadini MG, Ferrarini M, Doglioni C, Dagna L: BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Annals of the rheumatic diseases 74 (8), 1596-602, 2015.

Capper D, Reifenberger G: [Classification of gliomas. Current progress and perspectives]. Der Nervenarzt 86 (6), 672, 74-6, 78-80, passim, 2015.

Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A: Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 22 (3), 419-29, 2015.

Dinges HC, Capper D, Ritz O, Bruderlein S, Marienfeld R, von Deimling A, Moller P, Lennerz JK: Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Appl Immunohistochem Mol Morphol 2015.

Ecker J, Oehme I, Mazitschek R, Korshunov A, Kool M, Hielscher T, Kiss J, Selt F, Konrad C, Lodrini M, Deubzer HE, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T: Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun 3 (1), 22, 2015.

Ening G, Osterheld F, Capper D, Schmieder K, Brenke C: Risk factors for glioblastoma therapy associated complications. Clinical neurology and neurosurgery 134 55-9, 2015.

Ening G, Osterheld F, Capper D, Schmieder K, Brenke C: Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. Journal of cancer research and clinical oncology 141 (6), 1131-7, 2015.

Faulkner C, Ellis HP, Shaw A, Penman C, Palmer A, Wragg C, Greenslade M, Haynes HR, Williams H, Lowis S, White P, Williams M, Capper D, Kurian KM: BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum. J Neuropathol Exp Neurol 74 (9), 867-72, 2015.

Fontebasso AM, Shirinian M, Khuong-Quang DA, Bechet D, Gayden T, Kool M, De Jay N, Jacob K, Gerges N, Hutter B, Seker-Cin H, Witt H, Montpetit A, Brunet S, Lepage P, Bourret G, Klekner A, Bognar L, Hauser P, Garami M, Farmer JP, Montes JL, Atkinson J, Lambert S, Kwan T, Korshunov A, Tabori U, Collins VP, Albrecht S, Faury D, Pfister SM, Paulus W, Hasselblatt M, Jones DT, Jabado N: Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. Oncotarget 6 (31), 31844-56, 2015.

Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Backlund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, Verhaak RG, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C: Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathol 130 (3), 419-34, 2015.

Harter PN, Baumgarten P, Zinke J, Schilling K, Baader S, Hartmetz AK, Schittenhelm J, Beschorner R, Liebner S, Schulte D, Plate KH, Gutwein P, Korshunov A, Pfister SM, Jones DT, Doberstein K, Mittelbronn M: Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas. Neuropathol Appl Neurobiol 41 (2), 165-79, 2015.

Jakobiec FA, Kool M, Stagner AM, Pfister SM, Eagle RC, Proia AD, Korshunov A: Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC. American journal of ophthalmology 159 (6), 1065-74 e1, 2015.

Kessler T, Sahm F, Blaes J, Osswald M, Rubmann P, Milford D, Urban S, Jestaedt L, Heiland S, Bendszus M, Hertenstein A, Pfenning PN, Ruiz de Almodovar C, Wick A, Winkler F, von Deimling A, Platten M, Wick W, Weiler M: Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget 6 (31), 31050-68, 2015.

Koelsche C, Hovestadt V, Jones DT, Capper D, Sturm D, Sahm F, Schrimpf D, Adeberg S, Bohmer K, Hagenlocher C, Mechtersheimer G, Kohlhof P, Muhleisen H, Beschorner R, Hartmann C, Braczynski AK, Mittelbronn M, Buslei R, Becker A, Grote A, Urbach H, Staszewski O, Prinz M, Hewer E, Pfister SM, von Deimling A, Reuss DE: Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathol 25 (2), 202-08, 2015.

Korshunov A, Jakobiec FA, Eberhart CG, Hovestadt V, Capper D, Jones DT, Sturm D, Stagner AM, Edward DP, Eagle RC, Proia AD, Koch A, Ryzhova M, Ektova A, Schuller U, Zheludkova O, Lichter P, von Deimling A, Pfister SM, Kool M: Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology 35 (6), 538-44, 2015.

Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT: Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015.

Mack SC, Agnihotri S, Bertrand KC, Wang X, Shih DJ, Witt H, Hill N, Zayne K, Barszczyk M, Ramaswamy V, Remke M, Thompson Y, Ryzhova M, Massimi L, Grajkowska W, Lach B, Gupta N, Weiss WA, Guha A, Hawkins C, Croul S, Rutka JT, Pfister SM, Korshunov A, Pekmezci M, Tihan T, Philips JJ, Jabado N, Zadeh G, Taylor MD: Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res 21 (16), 3750-8, 2015.

Mock A, Warta R, Geisenberger C, Bischoff R, Schulte A, Lamszus K, Stadler V, Felgenhauer T, Schichor C, Schwartz C, Matschke J, Jungk C, Ahmadi R, Sahm F, Capper D, Glass R, Tonn JC, Westphal M, von Deimling A, Unterberg A, Bermejo JL, Herold-Mende C: Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget 6 (15), 13597-90, 2015.

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gommel M, Pauli M, Liao Y, Haring P, Pusch S, Herl V, Steinhauser C, Krunic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F: Brain tumour cells interconnect to a functional and resistant network. Nature 528 (7580), 93-98, 2015.

Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, Pusch S, Opitz CA, Blaes J, von Deimling A, Wick W, Platten M: Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia 63 (1), 78-90, 2015.

Ozolek JA, Cohen DE, Kool M, Pfister SM, Korshunov A, Bukowinski AJ, Davis AW: Medulloepithelioma with peculiar clinical presentation, stem cell phenotype and aberrant DNA-methylation profile. CNS oncology 4 (4), 203-12, 2015.

Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M, Pfister SM: Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27 (5), 728-43, 2015.

Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, Perry A: Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 28 (2), 187-200, 2015.

Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, Fabian J, Schober A, Fernekorn U, von Deimling A, Deubzer HE, Milde T, Witt O, Oehme I: Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 6 e1657, 2015.

Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DT, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn JC, Aldape K, Pfister SM, Korshunov A, Weller M, Herold-Mende C, Wick W, Brandner S, von Deimling A: Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130 (3), 407-17, 2015.

Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A: IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129 (6), 867-73, 2015.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A: ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129 (1), 133-46, 2015.

Sahm F, von Deimling A: Farewell to oligoastrocytoma: response to letters. Acta Neuropathol 129 (1), 155, 2015.

Schweizer L, Capper D, Holsken A, Fahlbusch R, Flitsch J, Buchfelder M, Herold-Mende C, von Deimling A, Buslei R: BRAF V600E analysis for the differentiation of papillary Craniopharyngiomas and Rathke's Cleft Cysts. Neuropathol Appl Neurobiol 41 (6), 733-42, 2015.

Thomas C, Ruland V, Kordes U, Hartung S, Capper D, Pietsch T, Gerss J, Wolff JE, Paulus W, Hasselblatt M: Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children. Acta Neuropathol 129 (6), 925-7, 2015.

Wang X, Dubuc AM, Ramaswamy V, Mack S, Gendoo DM, Remke M, Wu X, Garzia L, Luu B, Cavalli F, Peacock J, Lopez B, Skowron P, Zagzag D, Lyden D, Hoffman C, Cho YJ, Eberhart C, MacDonald T, Li XN, Van Meter T, Northcott PA, Haibe-Kains B, Hawkins C, Rutka JT, Bouffet E, Pfister SM, Korshunov A, Taylor MD: Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol 129 (3), 449-57, 2015.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Loffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Bostrom J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129 (5), 679-93, 2015.

Welzel G, Gehweiler J, Brehmer S, Appelt JU, von Deimling A, Seiz-Rosenhagen M, Schmiedek P, Wenz F, Giordano FA: Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis. J Neurooncol 124 (2), 265-73, 2015.

Woehrer A, Lau CC, Prayer D, Bauchet L, Rosenfeld M, Capper D, Fisher PG, Kool M, Muller M, Kros JM, Kruchko C, Wiemels J, Wrensch M, Danysh HE, Zouaoui S, Heck JE, Johnson KJ, Qi X, O'Neill BP, Afzal S, Scheurer ME, Bainbridge MN, Nousome D, Bahassi el M, Hainfellner JA, Barnholtz-Sloan JS: Brain Tumor Epidemiology - A Hub within Multidisciplinary Neuro-oncology. Report on the 15th Brain Tumor Epidemiology Consortium (BTEC) Annual Meeting, Vienna, 2014. Clin Neuropathol 34 (1), 40-6, 2015.

Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K, Belic J, Jones DT, Tschida B, Moriarity B, Largaespada D, Roussel MF, Korshunov A, Reifenberger G, Pfister SM, Lichter P, Kawauchi D, Gronych J: Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nature communications 6 7391, 2015.

2014

MGMT testing-the challenges for biomarker-based glioma treatment.
Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G.
Nat Rev Neurol. 2014 10(7):372-385


Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, von Deimling A, Davis T, Weiss WA, Loeffler M, Reifenberger G.
Int J Cancer. 2014 134(10):2437-2447


mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rubmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schnolzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2014 111(1):409-414


Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.
Reuss DE, Habel A, Hagenlocher C, Mucha J, Ackermann U, Tessmer C, Meyer J, Capper D, Moldenhauer G, Mautner V, Frappart PO, Schittenhelm J, Hartmann C, Hagel C, Katenkamp K, Petersen I, Mechtersheimer G, von Deimling A.
Acta Neuropathologica. 2014

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, Miller AK, von Deimling A.
Acta Neuropathol Commun. 2014 2(1):19


High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wohrer A, Hackl M, von Deimling A, Streubel B, Birner P.
Lung Cancer. 2014 83(83-89


Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.
Mesteri I, Bayer G, Meyer J, Capper D, Schoppmann SF, von Deimling A, Birner P.
Mod Pathol. 2014 27(1):135-144


Survival According to BRAF-V600 Tumor Mutations - An Analysis of 437 Patients with Primary Melanoma.
Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler T, Capper D, von Deimling A, Mittelbronn M, Perner S, Ikenberg K, Hantschke M, Büttner P, Garbe C, Weide B.
PLoS One. 2014 9(1):e86194


Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.
Marin C, Beauchet A, Capper D, Zimmermann U, Julie C, Ilie M, Saiag P, von Deimling A, Hofman P, Emile JF.
Arch Pathol Lab Med. 2014 138(1):71-75


Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.
Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jager N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis T, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, Agnihotri S, Cavalli FM, Clarke I, Nethery-Brokx K, Creasy CL, Verma SK, Koster J, Wu X, Yao Y, Milde T, Sin-Chan P, Zuccaro J, Lau L, Pereira S, Castelo-Branco P, Hirst M, Marra MA, Roberts SS, Fults D, Massimi L, Cho YJ, Van Meter T, Grajkowska W, Lach B, Kulozik AE, von Deimling A, Witt O, Scherer SW, Fan X, Muraszko KM, Kool M, Pomeroy SL, Gupta N, Phillips J, Huang A, Tabori U, Hawkins C, Malkin D, Kongkham PN, Weiss WA, Jabado N, Rutka JT, Bouffet E, Korbel JO, Lupien M, Aldape KD, Bader GD, Eils R, Lichter P, Dirks PB, Pfister SM, Korshunov A, Taylor MD.
Nature. 2014 506(7489):445-450


Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.
Litzenburger U, Opitz C, Sahm F, Rauschenbach K, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu X, Anastasov N, Lehmann I, Höfer T, von Deimling A, Wick W, Platten M.
Oncotarget. 2014 5(4):1038-1051


Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity.
Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones DT, Remke M, Northcott P, Perry A, Picard D, Rosenblum M, Antonelli M, Aronica E, Schuller U, Hasselblatt M, Woehrer A, Zheludkova O, Kumirova E, Puget S, Taylor MD, Giangaspero F, Peter Collins V, von Deimling A, Lichter P, Huang A, Pietsch T, Pfister SM, Kool M.
Acta Neuropathologica. 2014 128(2):279-289


Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, Konig R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schuller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM.
Cancer Cell. 2014 25(3):393-405


BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma.
Koelsche C, Sahm F, Paulus W, Mittelbronn M, Giangaspero F, Antonelli M, Meyer J, Lasitschka F, von Deimling A, Reuss D.
Neuropathology and Applied Neurobiology. 2014 40(3):337-344


Diagnostic Value of Immunohistochemistry for the Detection of the BRAF Mutation in Papillary Thyroid Carcinoma: Comparative Analysis with Three DNA-Based Assays.
Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.
Thyroid. 2014 24(5):858-866


GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik A, Witt O, Deubzer HE.
Cancer Research. 2014 74(9):565-572


NDRG1 prognosticates the natural course of disease in WHO grade II glioma.
Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thome CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W.
J Neurooncol. 2014 117(1):25-32

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.
Neuro Oncol. Epup ahead of print

TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, Wardelmann E, Schirmacher P, von Deimling A, Mechtersheimer G.
J Exp Clin Cancer Res. Epup ahead of print 33(1):33


Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiss EK, Schliesser MG, Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W.
Acta Neuropathologica. Epub ahead of print

A vaccine targeting mutant IDH1 induces antitumor immunity.
Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska A, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stpanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M.
Nature. Epub ahead of print

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Cako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Croul S.
Neuro Oncol. Epub ahead of print

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.
Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M.
Int J Cancer. Epub ahead of print

Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
Preusser M, Streubel B, Berghoff AS, Hainfellner JA, von Deimling A, Widhalm G, Dieckmann K, Wohrer A, Hackl M, Zielinski C, Birner P.
Histopathology. Epub ahead of print

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.
Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jager N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turanyi E, Hauser P, Sanden E, Darabi A, Siesjo P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM.
Nature. Epub ahead of print 511(7510):428-434


International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading.
Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Lopes MB, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P.
Brain Pathology. Epub ahead of print

Nuclear relocation of STAT6 reliably predicts NAB2/STAT6 fusion for the diagnosis of Solitary Fibrous Tumour.
Koelsche C, Schweizer L, Renner M, Warth A, Jones DT, Sahm F, Reuss DE, Capper D, Knosel T, Schulz B, Petersen I, Ulrich A, Renker EK, Lehner B, Pfister SM, Schirmacher P, von Deimling A, Mechtersheimer G.
Histopathology. Epub ahead of print

BRAF-Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and CD34 Expression.
Koelsche C, Sahm F, Wohrer A, Jeibmann A, Schittenhelm J, Kohlhof P, Preusser M, Romeike B, Dohmen-Scheufler H, Hartmann C, Mittelbronn M, Becker A, von Deimling A, Capper D.
Brain Pathology. Epub ahead of print

Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation.
Kickingereder P, Sahm F, Wiestler B, Roethke M, Heiland S, Schlemmer HP, Wick W, von Deimling A, Bendszus M, Radbruch A.
AJNR Am J Neuroradiol. Epub ahead of print

Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants.
Hutter S, Piro RM, Reuss DE, Hovestadt V, Sahm F, Farschtschi S, Kehrer-Sawatzki H, Wolf S, Lichter P, von Deimling A, Schuhmann MU, Pfister SM, Jones DT, Mautner VF.
Acta Neuropathologica. Epub ahead of print

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D.
Mod Pathol. Epub ahead of print

BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.
Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A, Sabbadini MG, Ferrarini M, Doglioni C, Dagna L.
Ann Rheum Dis. Epub ahead of print

Aberrant Self-Renewal and Quiescence Contribute to the Aggressiveness of Glioblastoma.
Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K, Bageritz J, Grabe N, von Deimling A, Beckhove P, Mogler C, Goidts V, Unterberg A, Eckstein V, Herold-Mende C.
J Pathol. Epub ahead of print

MAP kinase activity supported by BRAF mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, Schoppmann SF, Petzelbauer P, von Deimling A, Berger W, Preusser M.
Arch Dermatol Res. Epub ahead of print

2013

A complex secretory program orchestrated by the inflammasome controls paracrine senescence.
Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J.
Nat Cell Biol. 2013 15(8):978-990


Targeting the BRAF V600E Mutation in Multiple Myeloma.
Andrulis A, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho A, Goldschmidt H, Neben K, Raab M.
Cancer Discovery. 2013 3(8):862-869


Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
Baumgarten P, Harter PN, Tonjes M, Capper D, Blank AE, Sahm F, von Deimling A, Kolluru V, Schwamb B, Rabenhorst U, Starzetz T, Kogel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zornig M, Mittelbronn M.
Neuropathology and applied neurobiology. 2013

Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas.
Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, Radlwimmer B, Hojfeldt JW, Truffaux N, Castel D, Schubert S, Ryzhova M, Seker-Cin H, Gronych J, Johann PD, Stark S, Meyer J, Milde T, Schuhmann M, Ebinger M, Monoranu CM, Ponnuswami A, Chen S, Jones C, Witt O, Collins VP, von Deimling A, Jabado N, Puget S, Grill J, Helin K, Korshunov A, Lichter P, Monje M, Plass C, Cho YJ, Pfister SM.
Cancer Cell. 2013 24(5):660-672


Lack of BRAF V600E protein expression in primary central nervous system lymphoma.
Berghoff AS, Capper D, Preusser M.
Appl Immunohistochem Mol Morphol. 2013 21(4):351-353


Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma.
Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, Dewire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ.
Clin Cancer Res. 2013 19(24):6716-6729


Detection of the V600E BRAF mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H, Fischer A, Pham D, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F.
Hum Pathol. 2013 44(3):329-335


Immunohistochemical analysis of BRAFV600E-expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam K, Hedvat C, Pulitzer M, von Deimling A, Jungbluth A.
American Journal of Surgical Pathology. 2013 37(3):413-420


Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes.
Busam K, Sung J, Wiesner T, von Deimling A, Jungbluth A.
American Journal of Surgical Pathology. 2013 37(2):193-199


BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D, Voigt A, Bozukova G, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M.
Int J Cancer. 2013 133(7):1624-1630


Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution.
Colin C, Padovani L, Chappe C, Mercurio S, Scavarda D, Loundou A, Frassineti F, Andre N, Bouvier C, Korshunov A, Lena G, Figarella-Branger D.
Neuropath Appl Neurobiol. 2013 39(6):693-705


Detection of BRAF p.V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
Colomba E, Hélias-Rodzewicz Z, von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Côté J-F, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile J-F.
Journal of Molecular Diagnostics. 2013 7(11):e47595


Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
Deistung A, Schweser F, Wiestler B, Abello M, Roethke M, Sahm F, Wick W, Nagel AM, Heiland S, Schlemmer HP, Bendszus M, Reichenbach JR, Radbruch A.
PLoS One. 2013 8(3):e57924


Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S, Hullein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Frohling S, von Kalle C, Glimm H, Ho AD, Zenz T.
J Clin Oncol. 2013 31(19):e300-303


Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.
Dubuc AM, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, Kool M, Jones DT, Unterberger A, Morrissy AS, Shih D, Peacock J, Ramaswamy V, Rolider A, Wang X, Witt H, Hielscher T, Hawkins C, Vibhakar R, Croul S, Rutka JT, Weiss WA, Jones SJ, Eberhart CG, Marra MA, Pfister SM, Taylor MD.
Acta Neuropathol. 2013 125(3):373-384


BAF complexes facilitate decatenation of DNA by topoisomerase IIalpha.
Dykhuizen EC, Hargreaves DC, Miller EL, Cui K, Korshunov A, Kool M, Pfister S, Cho YJ, Zhao K, Crabtree GR.
Nature. 2013 497(7451):624-627


Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A, Jones DT, Witt H, Kool M, Albrecht S, Fleming A, Hadjadj D, Busche S, Lepage P, Montpetit A, Staffa A, Gerges N, Zakrzewska M, Zakrzewski K, Liberski PP, Hauser P, Garami M, Klekner A, Bognar L, Zadeh G, Faury D, Pfister SM, Jabado N, Majewski J.
Acta Neuropathologica. 2013 125(5):659-669


Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.
Goeppert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN, Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, Weller M, Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P, Plass C, Mittelbronn M.
J Neuropathol Exp Neurol. 2013 72(10):933-941


Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn J, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M.
Clinical Cancer Research. 2013 19(18):5146-5157


Bed isolation in experimental flap studies in rats: a dispensable procedure.
Heimer S, Schaefer A, Mueller W, Lass U, Gebhard MM, Germann G, Leimer U, Kollensperger E, Reichenberger MA.
Ann Plast Surg. 2013 70(3):354-359


Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays.
Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, Cavalli FM, Ramaswamy V, Zapatka M, Reifenberger G, Rutkowski S, Schick M, Bewerunge-Hudler M, Korshunov A, Lichter P, Taylor MD, Pfister SM, Jones DT.
Acta Neuropathologica. 2013 125(6):913-916


A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, Holzner B, Capper D, Preusser M, Marosi C, Oberndorfer S, Moik M, Buchroithner J, Seiz M, Tuettenberg J, Herrlinger U, Wick A, Vajkoczy P, Stockhammer G.
Neuro Oncol. 2013

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
Ilie M, Long E, Hofman V, Dadone B, Marquette C, Mouroux J, Vignaud J, Begueret H, Merlio J, Capper D, von Deimling A, Emile J-F, Hofman P.
Ann Oncol. 2013 24(3):742-748


Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer.
Jager N, Schlesner M, Jones DT, Raffel S, Mallm JP, Junge KM, Weichenhan D, Bauer T, Ishaque N, Kool M, Northcott PA, Korshunov A, Drews RM, Koster J, Versteeg R, Richter J, Hummel M, Mack SC, Taylor MD, Witt H, Swartman B, Schulte-Bockholt D, Sultan M, Yaspo ML, Lehrach H, Hutter B, Brors B, Wolf S, Plass C, Siebert R, Trumpp A, Rippe K, Lehmann I, Lichter P, Pfister SM, Eils R.
Cell. 2013

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
Jones D, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz H-J, Zichner T, Lambert S, Ryzhova M, Quang D, Fontebasso A, Stütz A, Hutter S, Zuckermann M, Sturm D, Gronych J, B L, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott P, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber U, Zapatka M, Raeder B, Schlesner M, Worth C, Bartholomae C, von Kalle C, Imbusch C, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik A, Ebinger M, Schuhmann M, Cho Y-J, Pomeroy S, von Deimling A, Witt O, Taylor M, Wolf S, Karajannis M, Eberhart C, Scheurlen W, Hasselblatt M, Ligon K, Kieran M, Korbel J, Yaspo M-L, Brors B, Felsberg J, Reifenberger G, Collins V, Jabado N, Eils R, Lichter P, Pfister S, Project38 obotIPT.
Nature Genetics. 2013 45(8):927-932


A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1.
Klink B, Miletic H, Stieber D, Huszthy P, Valenzuela J, Balss J, Wang J, Schubert M, Sakariassen P, Sundstrøm T, Torsvik A, Aarhus M, Mahesparan R, von Deimling A, Kaderali L, Niclou S, Schröck E, Bjerkvig R, JM. N.
PLoS one. 2013 8(3):e59773


Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A.
Acta Neuropathol. 2013 126(6):907-915


Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.
Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D.
Acta Neuropathologica. 2013 125(6):891-900


Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma.
Lambert SR, Witt H, Hovestadt V, Zucknick M, Kool M, Pearson DM, Korshunov A, Ryzhova M, Ichimura K, Jabado N, Fontebasso AM, Lichter P, Pfister SM, Collins VP, Jones DT.
Acta Neuropathologica. 2013

Protein kinase Cβ as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis.
Lanz T, Becker S, Osswald M, Bittner S, Schuhmann M, Opitz C, Gaikwad S, Wiestler B, Litzenburger U, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth S, Wick W, Platten M.
PNAS. 2013 110(36):14735-14740


Chromogenic In Situ Hybridization is a Reliable Alternative to Fluorescence In Situ Hybridization for Diagnostic Testing of 1p and 19q loss in paraffin embedded gliomas.
Lass U, Hartmann C, Capper D, Herold-Mende C, von Deimling A, Meiboom M, Mueller W.
Brain Pathology. 2013 23(3):311-318


The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, Pollak M, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH.
Cell. 2013 153(5):1064-1079


Highly prevalent TERT promoter mutations in bladder cancer and gliobastoma.
Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M.
Cell Cycle. 2013 12(10):1637-1638


Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long G, Wilmott J, Capper D, Preusser M, Zhang Y, Thompson J, Kefford R, von Deimling A, Scolyer R.
American Journal of Surgical Pathology. 2013 37(1):61-65


Emerging insights into the ependymoma epigenome.
Mack SC, Witt H, Wang X, Milde T, Yao Y, Bertrand KC, Korshunov A, Pfister SM, Taylor MD.
Brain Pathology. 2013 23(2):206-209


Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz I, Antonetti P, Pusch S, Capper D, Balss J, Voigt S, Weissert S, Mukrowsky A, Frank J, Senft C, Seifert V, von Deimling A, Kögel D.
Apoptosis. 2013 18(11):1416-1425


Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
Navis A, Niclou S, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers R, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden C, Wesseling P, Leenders W.
Acta Neuropathologica Communications. 2013 1(18):

Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.
Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M.
J Neuroimmunol. 2013 265(1-2):106-116


No Evidence for BRAF-V600E Mutations in Gastro-Esophageal Tumors: Results from a high-throughput Analysis of 534 Cases using a mutation-specific Antibody.
Preusser M, Berghoff A, Capper D, von Deimling A, Maroske F, Brodowicz T, Hejna M, Birner P, Schoppmann S.
Applied Immunohistochemistry & Molecular Morphology. 2013 21(5):426-430


Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies Preusser M, Berghoff A, Ilhan-Mutlu A, Dinhof C, Magerle M, Marosi C, Hejna M, Capper D, von Deimling A, Schoppmann S, Birner P.
Anticancer Research. 2013 33(3):1065-1071


ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
Preusser M, Berghoff A, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Woehrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann S, Zielinski C, Streubel B, Birner P.
Lung Cancer. 2013 80(3):278-283


Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M, Capper D, Berghoff A, Horvat R, Wrba F, Schindl M, Schoppmann S, von Deimling A, Birner P.
Applied Immunohistochemistry & Molecular Morphology. 2013 21(2):162-167


Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schuller U, Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, Pomeroy SL, Dunn S, Triscott J, Jabado N, Fontebasso A, Jones DT, Kool M, Karajannis MA, Gardner SL, Zagzag D, Nunes S, Pimentel J, Mora J, Lipp E, Walter AW, Ryzhova M, Zheludkova O, Kumirova E, Alshami J, Croul SE, Rutka JT, Hawkins C, Tabori U, Codispoti KE, Packer RJ, Pfister SM, Korshunov A, Taylor MD.
Lancet Oncol. 2013 14(12):1200-1207


Somatostatin receptor subtype 2 (sst(2)) is a potential prognostic marker and a therapeutic target in medulloblastoma.
Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, Gerss J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor MD, Pietsch T, Rutkowski S, Korshunov A, Monoranu CM, Fruhwald MC.
Childs Nerv Syst. 2013 29(8):1253-1262


TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, Jung S, Saad AG, Liau LM, Albrecht S, Zollo M, Cooper MK, Thompson RC, Delattre OO, Bourdeaut F, Doz FF, Garami M, Hauser P, Carlotti CG, Van Meter TE, Massimi L, Fults D, Pomeroy SL, Kumabe T, Ra YS, Leonard JR, Elbabaa SK, Mora J, Rubin JB, Cho YJ, McLendon RE, Bigner DD, Eberhart CG, Fouladi M, Wechsler-Reya RJ, Faria CC, Croul SE, Huang A, Bouffet E, Hawkins CE, Dirks PB, Weiss WA, Schuller U, Pollack IF, Rutkowski S, Meyronet D, Jouvet A, Fevre-Montange M, Jabado N, Perek-Polnik M, Grajkowska WA, Kim SK, Rutka JT, Malkin D, Tabori U, Pfister SM, Korshunov A, von Deimling A, Taylor MD.
Acta Neuropathol. 2013 126(6):917-929


Sensitivity of Malignant Peripheral Nerve Sheath Tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by Curcumin through induction of ROS.
Reuss D, Mucha J, Hagenlocher C, Ehemann V, Kluwe L, Mautner V, von Deimling A.
PLoS One. 2013 8(2):e57253


Functional MHC class II is up-regulated in Neurofibromin deficient Schwann cells Reuss D, Mucha J, Holtkamp N, Müller U, Berlien H-P, Mautner V-F, Ehemann V, Platten M, Scheffzek K, von Deimling A.
Journal of Investigative Dermatology. 2013 133(5):1372-1375


Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss D, Piro R, Jones D, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jäger N, Santarius T, Tarpey P, Stephens P, Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins V, König R, Wiestler O, Pfister S, von Deimling A.
Acta Neuropathologica. 2013 125(3):351-358


Nbn and Atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye.
Rodrigues P, Grigaravicius P, Remus M, Cavalheiro G, Gomes A, Martins M, Frappart L, Reuss D, McKinnon P, von Deimling A, Martins R, Frappart P-O.
PLoS One. 2013 8(7):e69209


AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
Sahm F, Bissel J, Koelsche C, Schweizer L, Capper D, Reuss D, Bohmer K, Lass U, Gock T, Kalis K, Meyer J, Habel A, Brehmer S, Mittelbronn M, Jones DT, Schittenhelm J, Urbschat S, Ketter R, Heim S, Mawrin C, Hainfellner JA, Berghoff AS, Preusser M, Becker A, Herold-Mende C, Unterberg A, Hartmann C, Kickingereder P, Collins VP, Pfister SM, von Deimling A.
Acta Neuropathologica. 2013 126(5):757-762


The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Sahm F, Opitz C, Ahrendt T, Radlwimmer B, Bode H, von Deimling A, Wick W, Platten M.
Cancer Research. 2013 73(11):3225-3234


Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein.
Schweizer L, Koelsche C, Sahm F, Piro R, Capper D, Reuss D, Pusch S, Habel A, Meyer J, Göck T, Jones D, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, König R, Wiestler O, Pfister S, von Deimling A.
Acta Neuropathologica. 2013 125(5):651-658


VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation.
Sperveslage J, Gierke M, Capper D, Honegger J, Sipos B, Beschorner R, Schittenhelm J.
Acta Neuropathologica. 2013 125(6):911-912


BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome.
Toon C, Walsh M, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters R, Clendenning M, Rosty C, Young J, A. W, Hopper J, Crook A, von Deimling A, Jenkins M, Buchanan D, Gill A.
American Journal of Surgical Pathology. 2013 37(10):1592-1602


Interlaboratory comparison of IDH mutation detection.
van den Bent M, Hartmann C, Preusser M, Ströbel T, Dubbink H, Kros J, von Deimling A, Sanson M, Halling K, Diefes K, Aldape K, Giannini C.
Journal of Neuro-Oncology. 2013 112(2):173-178


Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment.
Weiler M, Pfenning P-N, A-L. T, Blaes J, Jestaedt L, Gronych J, Dittmann L, Berger B, Jugold M, Kosch M, Combs S, von Deimling A, Weller M, Bendszus M, Platten M, Wick W.
Oncogene. 2013 32(9):1099-1109


Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
Neurology. 2013 81(17):1515-1521


Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Wick W, Steinbach J, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C, Combs S.
Neuro-Oncology. 2013 15(10):1405-1412


ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister S, Platten M, Weller M, Wick W.
Acta Neuropathol. 2013 126(3):443-451


Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Muller W, Plass C, Weller M, Wick W.
Neuro Oncol. 2013 15(8):1017-1026


BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
Wilmott J, Menzies A, Haydu L, Capper D, Preusser M, Zhang Y, Thompson J, Kefford R, von Deimling A, Scolyer R, Long G.
British Journal of Cancer. 2013 108(4):924-931


BRAF mutations in melanocytic nevi are fully clonal, consistent with an initiating role of BRAF in the formation of melanocytic neoplasia.
Yeh I, von Deimling A, Bastian B.
Journal of the National Cancer Institute. 2013 105(12):917-919

2012

A general G1/S-phase cell-cycle control module in the flowering plant Arabidopsis thaliana.
Zhao X, Harashima H, Dissmeyer N, Pusch S, Weimer AK, Bramsiepe J, Bouyer D, Rademacher S, Nowack MK, Novak B, Sprunck S, Schnittger A.
PLoS Genet. 2012 8(8):e1002847


Clonal selection drives genetic divergence of metastatic medulloblastoma.
Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG, Garzia L, Van Meter T, Zagzag D, Jabado N, Schwartzentruber J, Majewski J, Scheetz TE, Pfister SM, Korshunov A, Li XN, Scherer SW, Cho YJ, Akagi K, MacDonald TJ, Koster J, McCabe MG, Sarver AL, Collins VP, Weiss WA, Largaespada DA, Collier LS, Taylor MD.
Nature. 2012 482(7386):529-533


Molecular approaches to ependymoma: the next step(s).
Witt H, Korshunov A, Pfister SM, Milde T.
Curr Opin Neurol. 2012 25(6):745-750


DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis.
von Bueren AO, Gerss J, Hagel C, Cai H, Remke M, Hasselblatt M, Feuerstein BG, Pernet S, Delattre O, Korshunov A, Rutkowski S, Pfister SM, Baudis M.
J Neurooncol. 2012 109(2):415-423


The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis.
Vo DT, Subramaniam D, Remke M, Burton TL, Uren PJ, Gelfond JA, de Sousa Abreu R, Burns SC, Qiao M, Suresh U, Korshunov A, Dubuc AM, Northcott PA, Smith AD, Pfister SM, Taylor MD, Janga SC, Anant S, Vogel C, Penalva LO.
Am J Pathol. 2012 181(5):1762-1772


Molecular subgroups of medulloblastoma: the current consensus.
Taylor M, Northcott P, Korshunov A, Remke M, Cho Y-J, Clifford S, Eberhart C, Parsons W, Rutkowski S, Gajjar A, Ellison D, Lichter P, Gilbertson R, Pomeroy S, Kool M, Pfister S.
Acta Neuropathologica. 2012 123(4):465-472


Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma.
Sturm D, Witt H, Hovestadt V, Khuong Quang D-A, Jones D, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu X-Y, Fontebasso A, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann M, van Meter T, Frühwald M, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik A, Madden J, Donson A, Foreman N, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm C, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth A, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski P, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Tayler M, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins V, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister S.
Cancer Cell. 2012 22(4):425-437


IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
Stockhammer F, Misch M, Helms H, Lengler U, Prall F, von Deimling A, Hartmann C.
Seizure. 2012 21(3):194-197


Detection of V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.
Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P.
Journal of the American Academy of Dermatology. 2012 67(3):488-491


Driver mutations in histone H3.3 and chromatin remodelling genes in pediatric glioblastoma.
Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K, Sturm D, Fontebasso A, Khuong Quang D, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel J, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann M, Scheurlen W, Pekrun A, Frühwald M, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski P, Dong Z, Siegel P, Kulozik A, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins V, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister S, Jabado N.
Nature. 2012 492(7384):226-231


CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F, Kölsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C.
Acta Neuropathologica. 2012 123(6):853-860


Detection of 2-Hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas-chromatography/mass-spectrometry.
Sahm F, Capper D, Pusch S, Balss J, Koch A, Langhans C, Okun J, von Deimling A.
Brain Pathology. 2012 22(1):26-31


BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans Cell Histiocytosis.
Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka A, Berghoff A-S, Habel A, Schneider M, Kulozik A, Anagnostopoulos I, Müllauer L, Mechtersheimer G, von Deimling A.
Blood. 2012 120(12):e28-34


Addressing diffuse glioma as a systemic brain disease with single-cell analysis.
Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D, von Deimling A.
Archives of Neurology. 2012 69(4):523-526


MYC family amplification and clinical risk factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan S, Schwalbe E, Cole M, Lu Y, Lusher M, Megahed H, O’Toole K, Nicholson S, Bognar L, Garami M, Hauser P, Korshunov A, Pfister S, Williamson D, Taylor R, Ellison D, Bailey S, Clifford S.
Acta Neuropathologica. 2012 123(4):501-513


Distinct requirement for an intact dimer interface in wildtype, V600E and kinase-dead B-Raf signalling.
Röring M, Herr R, Fiala G, Heilmann K, Braun S, Eisenhardt A, Halbach S, Capper D, von Deimling A, Schamel W, Saunders D, Brummer T.
EMBO. 2012 31(11):2629 - 2647


Fibrin-Embedded Adipose Derived Stem Cells Enhance Skin Flap Survival.
Reichenberger MA, Mueller W, Schafer A, Heimer S, Leimer U, Lass U, Germann G, Kollensperger E.
Stem Cell Rev. 2012

Adipose Derived Stem Cells Protect Skin Flaps Against Ischemia-Reperfusion Injury.
Reichenberger MA, Heimer S, Schaefer A, Lass U, Gebhard MM, Germann G, Leimer U, Kollensperger E, Mueller W.
Stem Cell Rev. 2012

Extracorporeal shock wave treatment protects skin flaps against ischemia- reperfusion injury.
Reichenberger MA, Heimer S, Schaefer A, Lass U, Gebhard MM, Germann G, Engel H, Kollensperger E, Leimer U, Mueller W.
Injury. 2012 43(3):374-380


Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations.
Rausch T, Jones D, Zapatka M, Stütz A, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott P, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik A, Witt O, Martin D, Zhang C, Porat R, Merino D, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker F, Döhner K, Döhner H, Koster J, Molenaar J, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor M, Lichter P, Pfister S, Korbel J.
Cell. 2012 148(1-2):59-71


Identification of kinase substrates by bimolecular complementation assays.
Pusch S, Harashima H, Schnittger A.
Plant J. 2012 70(2):348-356


Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis.
Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TS, Kim SK, Ra YS, Fangusaro J, Korshunov A, Toledano H, Nakamura H, Hayden JT, Chan J, Lafay-Cousin L, Hu P, Fan X, Muraszko KM, Pomeroy SL, Lau CC, Ng HK, Jones C, Van Meter T, Clifford SC, Eberhart C, Gajjar A, Pfister SM, Grundy RG, Huang A.
Lancet Oncol. 2012

An animal model of MYC-driven medulloblastoma.
Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.
Cancer Cell. 2012 21(2):155-167


Promotion of glioma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M, Litzenburger U, Sahm F, K. R, Tudoran R, C. H, Marquez V, von Deimling A, Wick W, Platten M.
PLoS One. 2012 7(10):e47663


Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.
Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, Eberhart CG, Dubuc A, Guettouche T, Cardentey Y, Bouffet E, Pomeroy SL, Marra M, Malkin D, Rutka JT, Korshunov A, Pfister S, Taylor MD.
Acta Neuropathologica. 2012 123(4):615-626


The clinical implications of medulloblastoma subgroups.
Northcott PA, Korshunov A, Pfister SM, Taylor MD.
Nat Rev Neurol. 2012 8(6):340-351


Medulloblastomics: the end of the beginning.
Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM.
Nat Rev Cancer. 2012 12(12):818-834


Subgroup specific structural variation across 1,000 medulloblastoma
Genomes.
Northcott P, Shih D, Peacock J, Garzia L, Morrissy S, Zichner T, Stütz A, Korshunov A, Reimand J, Schumacher S, Beroukhim R, Ellison D, Marshall C, Lionel A, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli F, Wang X, Remke M, Wu X, Chiu R, Chu A, Chuah E, Corbett R, Hoad G, Jackman S, Li Y, Lo A, Mungall K, Nip K, Qian J, Raymond A, Thiessen N, Varhol R, Birol I, Moore R, Mungall A, Holt R, Kawauchi D, Roussel M, Kool M, Jones D, Witt H, Fernandez A, Kenney A, Wechsler-Reya R, Dirks P, Aviv T, Grajkowska W, Perek-Polnik M, Haberler C, Delattre O, Reynaud S, Doz F, Pernet-Fattet S, Cho B-K, Kim S-K, Wang K-C, Scheurlen W, Eberhart C, Fèvre-Montange M, Jouvet A, Pollack I, Fan X, Muraszko K, Gillespie G, Di Rocco C, Massimi L, Michiels E, Kloosterhof N, French P, Kros J, Olson J, Ellenbogen R, Zitterbart K, Kren L, Thompson R, Cooper M, Lach B, McLendon R, Bigner D, Fontebasso A, Albrecht S, Jabado N, Lindsey J, Bailey S, Gupta N, Weiss W, Bognár L, Klekner A, Van Meter T, Kumabe T, Tominaga T, Elbabaa S, Leonard J, Rubin J, Liau L, Van Meir E, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad A, Iolascon A, Jung S, Carlotti C, Vibhakar R, Ra Y, Robinson S, Zollo M, Faria C, Chan J, Levy M, Sorensen P, Meyerson M, Pomeroy S, Cho Y-J, Bader G, Tabori U, Hawkins C, Bouffet E, Scherer S, Rutka J, Malkin D, Clifford S, Jones S, Korbel J, Pfister S, Marra M, Taylor M.
Nature. 2012 488(7409):49-56


HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, Antunes AS, Oehme I, Pekrun A, Pfister SM, Kulozik AE, Witt O, Deubzer HE.
J Neurooncol. 2012 110(3):335-348


Nestin expression identifies ependymoma patients with poor outcome.
Milde T, Hielscher T, Witt H, Kool M, Mack S, Deubzer H, Oehme I, Lodrini M, Benner A, Taylor M, von Deimling A, Kulozik A, Pfister S, Witt O, Korshunov A.
Brain Pathology. 2012 22(6):848-860


Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, von Deimling A, Breitling R, Doerr H, Rödel F, Speidel D, Cinatl J.
Cell Death and Disease. 2012 5(3):e294


A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue Origin.
Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, Huszar M, Fogt F, Ashkenazi K, Sanden M, Goren E, Dromi N, Zion O, Burnstein I, Chajut A, Spector Y, Aharonov R.
Oncologist. 2012 17(6):801-812


Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Loussouarn D, Le Loupp A, Frenel J, Leclair F, von Deimling A, Aumont M, Martin S, Campone M, Denis M.
International Journal of Oncology. 2012 40(6):2058-2062


Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, Tonjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N.
Acta Neuropathologica. 2012 124(5):615-625


Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke D, Pfenning PN, Sahm F, Klein AK, Kempf T, Warnken U, Schnolzer M, Tudoran R, Weller M, Platten M, Wick W.
Clinical Cancer Research. 2012 18(1):105-117


ATR maintains select progenitors during nervous system development.
Lee Y, Shull ER, Frappart PO, Katyal S, Enriquez-Rios V, Zhao J, Russell HR, Brown EJ, McKinnon PJ.
EMBO J. 2012 31(5):1177-1189


Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.
Lass U, Nümann A, von Eckardstein K, Kiwit J, Stockhammer F, Horaczek J, Veelken J, Herold-Mende C, Jeuken J, von Deimling A, Mueller W.
PLoS One. 2012 7(7):e41298


LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR).
Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, Koster J, Versteeg R, Cowdrey C, Perry A, Picard D, Rosenblum M, Giangaspero F, Aronica E, Schuller U, Hasselblatt M, Collins VP, von Deimling A, Lichter P, Huang A, Pfister SM, Kool M.
Acta Neuropathologica. 2012 124(875-881


Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A, Remke M, Kool M, Hielscher T, Northcott P, Williamson D, Pfaff E, Witt H, Jones D, Ryzhova M, Cho Y-J, Wittmann A, Benner A, Weiss W, von Deimling A, Scheurlen W, Kulozik A, Clifford S, Collins V, Westermann F, Taylor M, Lichter P, Pfister S.
Acta Neuropathologica. 2012 123(4):515-527


Immunohistochemical Detection of the BRAF V600E mutated Protein in Papillary Thyroid Carcinoma Koperek O, Kornauth C, Capper D, Berghoff A, Asari R, Niederle B, von Deimling A, Birner P, Preusser M.
American Journal of Surgical Pathology 2012 36(6):844-850


Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Backlund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM.
Acta Neuropathol. 2012 123(4):473-484


K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu X-Y, Fontebasso A, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones D, Majewski J, Pfister S, Jabado N, Hawkins C.
Acta Neuropathologica. 2012 124(3):439-447


T cell Activation Is Driven by an ADP-Dependent Glucokinase Linking Enhanced Glycolysis with Mitochondrial Reactive Oxygen Species Generation.
Kaminski MM, Sauer SW, Kaminski M, Opp S, Ruppert T, Grigaravicius P, Grudnik P, Grone HJ, Krammer PH, Gulow K.
Cell Rep. 2012 2(5):1300-1315


Dissecting the genomic complexity underlying medulloblastoma.
Jones D, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho Y-J, Pugh T, Hovestadt V, Stütz A, Rausch T, Warnatz H-J, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber U, Wang Q, Lasitschka B, Bartholomae C, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts M, Russell R, Coco S, Tonini G, Schüller U, Hans V, Graf N, Kim Y-J, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik A, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann M, Frühwald M, Hasselblatt M, Jabado N, Rutkowski S, von Bueren A, Williamson D, Clifford S, McCabe M, Collins V, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott P, Taylor M, Meyerson M, Pomeroy S, Yaspo M-L, Korbel J, Korshunov A, Eils R, Pfister S, Lichter P.
Nature. 2012 488(7409):100-105


Bone marrow biopsies of patients with haematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology.
Hehne S, Schäfer S, Richter P, Geier C, Chen Y, von Deimling A, Petersen I.
Pathology - Research and Practice. 2012 208(9):510-517


Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Hegi M, Janzer R, Lambiv W, Gorlia T, Kouwenhoven M, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens A-C, Hamou M-F, Bady P, Weller M, van den Bent M, Mason W, Mirimanoff R-O, Stupp R, Mokhtari K, Wesseling P.
Acta Neuropathologica. 2012 123(6):841-852


High prevalence of BRAF V600E mutations in Edrheim-Chester Disease but not in other non-Langerhans cell histiocytoses.
Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, Schmalzing M, Croockewit S, Kambouchner M, Copin M-C, Fraitag S, Sahm F, Brousse N, Amoura Z, Donadieu J, Emile J-F.
Blood. 2012 120(13):2700-2703


RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, Toedt G, Campos B, Korshunov A, Momma S, Van Schaftingen E, Reifenberger G, Herold-Mende C, Lichter P, Radlwimmer B.
Oncogene. 2012 31(27):3235-3243


Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M.
PLoS One. 2012 7(3):e33449


2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
Capper D, Simon M, Langhans C-D, Okun J, Tonn J, Weller M, von Deimling A, Hartmann C, Network ftGG.
International Journal of Cancer. 2012 131(3):766-768


Clinical neuropathology practice news 2-2012: BRAF V600E testing.
Capper D, Berghoff A-S, von Deimling A, Preusser M.
Clin Neuropathol. 2012 31(2):64-66


Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.
Capper D, Berghoff A, Magerle M, Ilhan A, Wöhrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M.
Acta Neuropathologica. 2012 123(22):223-233


Epigenetically mediated downregulation of the differentiation - promoting chaperon protein CRABP2 in astrocytic gliomas.
Campos B, Warta R, Chaisaingmongkol J, Geiselhart L, Popanda O, Hartmann C, von Deimling A, Unterberg A, Plass C, Schmezer P, Herold-Mende C.
International Journal of Cancer. 2012 8):1963-1968


Utilisation of a monoclonal antibody for BRAFV600E detection in papillary thyroid carcinoma.
Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Delbridge L, Robinson B, Learoyd D, Capper D, von Deimling A, Clifton-Blight R, Gill A.
Endocrine-Related Cancer. 2012 19(6):779-784


Impaired Pten expression in human malignant peripheral nerve sheath tumours.
Bradtmöller M, Hartmann C, Zietsch J, Jäschke S, Mautner V, Kurtz A, Baier M, Harder A, Reuss D, von Deimling A, Heppner F, Holtkamp N.
PLoS One. 2012 7(11):e47595


Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis.
Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, Sutton I, Lassmann H, Bauer J.
Brain. 2012 135(Pt 5):1622-1638


Hedgehog-mediated regulation of PPARgamma controls metabolic patterns in neural precursors and shh-driven medulloblastoma.
Bhatia B, Potts CR, Guldal C, Choi S, Korshunov A, Pfister S, Kenney AM, Nahle ZA.
Acta Neuropathol. 2012 123(4):587-600


Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Balss J, Pusch S, Beck A-C, Herold-Mende C, Krämer A, Thiede C, Buckel W, Langhans C-D, Okun J, von Deimling A.
Acta Neuropathologica. 2012 124(6):883-891


MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma.
Bai A, Milde T, Remke M, Rolli C, Hielscher T, Cho Y-J, Kool M, Northcott P, Jugold M, Bazhin A, Eichmüller S, Kulozik A, Pscherer A, Benner A, Taylor M, Pomeroy S, Kemkemer R, Witt O, Korshunov A, Lichter P, Pfister S.
Acta Neuropathologica. 2012 123(4):529-538


The Wnt secretion protein Evi/Gpr177  promotes glioma tumourigenesis.
Augustin I, Goidts V, Bongers A, Kerr G, Vollert G, Radlwimmer B, Hartmann C, Herold-Mende C, Reifenberger G, von Deimling A, Boutros M.
EMBO Mol Med. 2012 4(1):38-51


Application of a BRAF V600E mutation-specific antibody for the diagnosis of Hairy Cell Leukemia.
Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D.
American Journal of Surgical Pathology. 2012 36(12):1796-1800


No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C, Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C.
Journal of Neuro-Oncology. 2012 109(1):15-22


Long-term Outcome After Radiotherapy in Patients with Atypical and Malignant Meningiomas-Clinical Results in 85 Patients Treated in a Single Institution Leading to Optimized Guidelines for Early Radiation Therapy.
Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Debus J, Combs SE.
International Journal of Radiation Oncology, Biology, Physics. 2012 83(3):859-864

2011

Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression.
Woehrer A, Slavc I, Peyrl A, Czech T, Dorfer C, Prayer D, Stary S, Streubel B, Ryzhova M, Korshunov A, Pfister SM, Haberler C.
Acta Neuropathologica. 2011 122(6):787-790


FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS).
Woehrer A, Sander P, Haberler C, Kern S, Maier H, Preusser M, Hartmann C, Kros JM, Hainfellner JA.
Clin Neuropathol. 2011 30(2):47-55


Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.
Witt H, Mack S, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones D, Northcott P, Garcia L, Bertrand K, Wittmann A, Yao Y, Roberts S, Massimi L, van Meter T, Weiss W, Gupta N, Grajkowska W, Lach B, Cho J, von Deimling A, Kulozik A, Witt O, Bader G, Hawkins C, Guha A, Rutka J, Lichter P, Korshunov A, Taylor M, Pfister S.
Cancer Cell. 2011 20(2):143-157


R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 alpha upregulation in adult glioma.
Williams S, Karajannis M, Chiriboga L, von Deimling A, Zagzag D.
Acta Neuropathologica. 2011 121(2):279-281


Molecular Signatures Classify Astrocytic Gliomas by IDH1 Mutation Status.
Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel M, Hofmann M, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler O, Hahn M, Lichter P, Reifenberger G, Radlwimmer B.
International Journal of Cancer. 2011 128(5):1095-1103


The p53 tumor suppressor is stabilized by Inhibitor of Growth 1 (ING1) by blocking polyubiquitination.
Thalappilly S, Feng X, Pastyryeva S, Suzuki K, Muruve D, Larocque D, Richard S, Truss M, von Deimling A, Riabowol K, Tallen G.
PLoS One. 2011 6(6):e21065


The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study.
Schneider T, Reuss D, Warth A, Schnabel PA, von Deimling A, Herth FJ, Dienemann H, Hoffmann H.
European Journal of Cardio-Thoracic Surgery. 2011 39(6):968-973


Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma and ganglioglioma.
Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis D, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A.
Acta Neuropathologica. 2011 121(3):397-405


Immunohistochemical analysis of 1844 human epithelial and hematopoietic tumors and sarcomas for IDH1R132H mutation.
Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, Mechterheimer G, Petersen I, Paulus W, von Deimling A.
Histopathology. 2011 58(7):1167-1172


Adult Medulloblastoma is Comprised of Three Major Molecular Variants.
Remke M, Hielscher T, Northcott P, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik A, Lichter P, Taylor M, Pfister S, Korshunov A.
Journal of Clinical Oncology. 2011 29(19):2717-2723


FSTL5 is a marker of poor prognosis in Non-WNT/Non-SHH medulloblastoma.
Remke M, Hielscher T, Korshunov A, Northcott P, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren A, von Deimling A, Rutkowski S, Scheurlen W, Kulozik A, Taylor M, Lichter P, Pfister S.
Journal of Clinical Oncology. 2011 29(29):3852-3861


Glioma IDH1 mutation patterns off the beaten track.
Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A.
Neuropathology and Applied Neurobiology. 2011 37(4):428-430


Bimolecular-fluorescence complementation assay to monitor kinase-substrate interactions in vivo.
Pusch S, Dissmeyer N, Schnittger A.
Methods Mol Biol. 2011 779(245-257


IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
Preusser M, Capper D, Hartmann C.
Clin Neuropathol. 2011 30(5):217-230


Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Paulsson J, Lindh M, Jarvius M, Puputti M, Nister M, Nupponen N, Paulus W, Söderberg O, Dresemann G, von Deimling A, Joensuu H, Östman A, Hasselblatt M.
International Journal of Cancer. 2011 128(8):1981-1988


The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M.
PLoS One. 2011 6(5):e19823


An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
Opitz C, Litzenburger U, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin G, Miller C, Lutz C, Radlwimmer B, Lehman I, von Deimling A, Wick W, Platten M.
Nature. 2011 478(7368):197-203


Medulloblastoma Comprises Four Distinct Molecular Variants.
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD.
Journal of Clinical Oncology. 2011 29(11):1408-1414


Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.
Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, Al-Halabi H, Albrecht S, Jabado N, Eberhart CG, Grajkowska W, Weiss WA, Clifford SC, Bouffet E, Rutka JT, Korshunov A, Pfister S, Taylor MD.
Acta Neuropathologica. 2011 122(2):231-240


Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits.
Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF.
The Journal of pediatrics. 2011 159(4):652-655 e652


The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors.
Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M, Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A.
Invest Radiol. 2011 46(9):539-547


Accurate classification of metastatic brain tumors using a novel microRNA-based test.
Mueller WC, Spector Y, Edmonston TB, St Cyr B, Jaeger D, Lass U, Aharonov R, Rosenwald S, Chajut A.
Oncologist. 2011 16(2):165-174


Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma.
Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, Hayden JT, Dyer S, Pfister S, Korshunov A, Brundler MA, Lowe J, Coyle B, Grundy RG.
Neuro-Oncology. 2011 13(8):866-879


A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp H-G, Jugold M, Deubzer H, Oehme I, Lodrini M, H-J. G, Benner A, Brüstle O, Gilbertson R, von Deimling A, Kulozik A, Pfister S, Martin-Villalba A, Witt O.
Acta Neuropathologica. 2011 122(5):637-650


Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Weber K, Fehse B, Mack E, Stiewe T, Doerr H, Speidel D, Cinatl jr. J.
Cell Death & Disease. 2011 2(e243


Hot spots in 18FET-PET delineate malignant tumor parts within suspected WHO grade II glioma.
Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn J, Kretzschmar H, Poepperl G, Kreth F.
Neuro-Oncology. 2011 13(3):307-316


MIA is a potential biomarker for tumour load in neurofibromatosis type 1.
Kolanczyk M, Mautner V, Kossler N, Nguyen R, Kuhnisch J, Zemojtel T, Jamsheer A, Wegener E, Thurisch B, Tinschert S, Holtkamp N, Park SJ, Birch P, Kendler D, Harder A, Mundlos S, Kluwe L.
BMC medicine. 2011 9(82


Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
Jacob K, Quang-Khuong DA, Jones DT, Witt H, Lambert S, Albrecht S, Witt O, Vezina C, Shirinian M, Faury D, Garami M, Hauser P, Klekner A, Bognar L, Farmer JP, Montes JL, Atkinson J, Hawkins C, Korshunov A, Collins VP, Pfister SM, Tabori U, Jabado N.
Clinical Cancer Research. 2011 17(14):4650-4660


Molecular markers in low-grade gliomas: predictive or prognostic?
Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller W.
Clinical Cancer Research. 2011 17(13):4588-4599


An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice.
Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DT, Witt O, Heiland S, Bendszus M, Holland EC, Pfister S, Lichter P.
J Clin Invest. 2011 121(4):1344-1348


Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P.
J Neurooncol. 2011 104(3):801-809


Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation.
Gessi M, Pfister S, Hans VH, Korshunov A, Pietsch T.
Acta Neuropathologica. 2011 121(2):283-285


Identification of diagnostic serum protein profiles of glioblastoma patients.
Elstner A, Stockhammer F, Nguyen-Dobinsky T-N, Nguyen Q, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza R, von Deimling A, Kurtz A.
Journal of Neuro-Oncology. 2011 102(1):71-80


PROX1 is a predictor of survival for gliomas WHO grade II.
Elsir T, Qu M, Berntsson S, Orrego A, Olofsson T, Lindström M, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A.
Brit J Cancer. 2011 104(11):1747-1754


Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Van Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T.
Int J Cancer. 2011 129(9):2297-2303


Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression Desestret A, Ciccarino P, Ducray F, Crinière E, Boisselier B, Labussiere M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre J, Mokhtari K, Sanson M.
Journal of Neuro-Oncology. 2011 105(2):219-224


Improved correlation of neuropathological classification according to the adapted WHO classification and outcome after radiation therapy in patients with atypical and anaplastic meningiomas.
Combs S, Schulz-Ertner D, Debus J, von Deimling A, Hartmann C.
International Journal of Radiation Oncology Biology Physics. 2011 81(5):1415-1421


Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
Combs S, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C.
Radiation Oncology. 2011 6(115


Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative  mechanism of MAPK pathway activation in pilocytic astrocytoma Cin H, Meyer C, Herr R, Janzarik W, Lambert S, Jones D, KJacob K, A. B, Witt H, Remke M, Bender S, Falkenstein F, Anh T, Olbrich H, von Deimling A, Pekrun A, Kulozik A, Gnekow A, Scheuerlen W, Witt O, Omran H, Jabado N, Collins P, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister S.
Acta Neuropathologica. 2011 121(6):763-774


Mutation specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter P, Jeibmann A, von Deimling A.
Acta Neuropathologica. 2011 121(2):241-252


Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation specific monoclonal antibody.
Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.
Acta Neuropathologica. 2011 122(1):11-19


Mutational analysis of D2HGDH and L2HGDH in brain tumors without IDH1 or IDH2 mutations.
Brehmer S, Pusch S, Schmieder K, von Deimling A, Hartmann C.
Neuropathology and Applied Neurobiology. 2011 37(3):330-332


Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E, Brems H, Daniels B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van Den Bruel A, de Ravel T, Cichowski K, Kluwe L, Mautner V, Sciot R, Legius E.
Genes, chromosomes & cancer. 2011 50(12):1021-1032


Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors.
Barbus S, Tews B, Karra D, Hahn M, Radlwimmer B, Delhomme N, Hartmann C, Felsberg J, Krex D, Schackert G, Martinez R, Reifenberger G, Lichter P.
J Natl Cancer Inst. 2011 103(7):598-606

2010

The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment Zietsch J, Ziegenhagen N, Reuss D, Heppner F, von Deimling A, Holtkamp N.
PLoS One. 2010 5(7):e11858


Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M, Hartmann C, Wiewroth D, Herrlinger U, Gorlia T, Bahr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W.
International Journal of Radiation Oncology Biology Physics 2010 77(3):670-676


Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma.
Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott P, Witt H, Ryzhova M, Felsberg J, Benner A, Riester S, Scheurlen W, Grunewald T, von Deimling A, Kulozik A, Reifenberger G, Taylor M, Lichter P, E. B, Pfister S.
Cancer Research. 2010 70(20):8003-8014


The Inhibitor of Growth 1 (ING1) is involved in Trichostatin A-induced apoptosis and caspase 3-signaling in p53-deficient glioblastoma cells.
Tammanai M, Farhangi S, Truss M, Sinn B, Wurm R, Henze G, Riabowol K, von Deimling A, Tallen G.
Oncology Research. 2010 18(10):469-480


Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.
Sellner L, Capper D, Meyer J, Langhans C, Hartog C, Pfeifer H, Ho A, Okun J, Krämer A, von Deimling A.
European Journal of Haematology. 2010 85(5):457-459


Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C.
Acta Neuropathologica. 2010 120(2):261-267


Sorafenib plus valproic acid for infant spinal glioblastoma.
Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S, Wolff JE.
Joural of Pediatric Hematology Oncology. 2010 32(6):511-514


Molecular diagnostics of CNS embryonal tumors.
Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD.
Acta Neuropathologica. 2010 120(5):553-566


TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma.
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren A, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik A, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor M, Tabori U, Lichter P, Korshunov A, Pfister S.
Journal of Clinical Oncology. 2010 28(35):5188-5196


HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, Deubzer H, Lodrini M, Taylor M, von Deimling A, Pfister S, Witt O.
Clinical Cancer Research. 2010 16(12):3240-3252


PCR and Restriction Endonuclease based Detection of IDH1 Mutations.
Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, Hartmann C, von Deimling A.
Brain Pathology. 2010 20(2):298-300


Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival.
McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, von Deimling A, Wheeler HR, Cook RJ, Biggs MT, Little NS, Robinson BG, Reddel RR, Royds JA.
Journal of Neuropathology and Experimental Neurology. 2010 69(7):729-736


Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region.
Lueth M, von Deimling A, Pietsch T, Wong L, KLurtz A, Henze G, Driever P.
Journal of Pediatric Hematology Oncology. 2010 32(2):156-159


Molecular staging of intracranial ependymoma in children and adults.
Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schöttler A, Kulozik A, Witt O, von Deimling A, Lichter P, Pfister S.
Journal of Clinical Oncology. 2010 28(19):3182-3190


Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik A, von Deimling A, Lichter P, Pfister S.
Journal of Clinical Oncology. 2010 28(18):3054-3060


Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes.
Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt H, Tobias V, Buccoliero A, Sardi I, Gardiman M, Bonnin J, Scheithauer B, Kulozik A, Witt O, Mork S, von Deimling A, Wiestler O, Giangaspero F, Rosenblum M, Pietsch T, Lichter P, Pfister S.
Acta Neuropathologica. 2010 120(2):253-260


Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1 mutated glioblastomas and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.
Acta Neuropathologica. 2010 120(6):707-718


Imatinib Mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.
Demestre M, Holtkamp N, Herzberg J, Hagel C, Reuss D, Friedrich R, Kluwe L, von Deimling A, Mautner V-F, Kurtz A.
Journal of Neuro-Oncology. 2010 98(1):11-19


Carbon ion radiation therapy for high-risk meningiomas Combs S, Hartmann C, Nikoghosyan A, Jäkel O, Karger C, Haberer T, von Deimling A, Münter M, Huber P, Debus J, Schulz-Ertner D.
Radiotherapy and Oncology 2010 95(1):54-59


Characterization of R132H Mutation Specific IDH1 Antibody binding in brain tumors.
Capper D, Weißert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A.
Brain Pathology. 2010 20(1):245-254


Application of mutant IDH1 antibody to differentiate diffuse glioma from non-neoplastic central nervous system lesions and therapy induced changes.
Capper D, Sahm S, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J.
American Journal of Surgical Pathology. 2010 34(8):1199-1204


Defective p53 antiangiogenic signaling in glioblastoma.
Berger B, Capper D, Lemke D, Pfenning P-N, Platten M, Weller M, von Deimling A, Wick W, Weiler M.
Neuro-Oncology. 2010 12(9):894-907


Inositol-requiring enzyme 1{alpha} is a key regulator of angiogenesis and invasion in malignant glioma.
Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, Magnin N, A. F, Maitre M, Gaiser T, von Deimling A, Czabanka M, Vajkoczy P, Chevet E, Bikfalvi A, Moenner M.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2010 107(35):15553-15558


IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.
Andrulis M, Capper D, Meyer J, Penzel R, Hartmann C, Zentgraf H, von Deimling A.
Haematologica. 2010 95(10):1623-1627


Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation specific antibody and direct sequencing.
Andrulis M, Capper D, Luft T, Hartmann C, Zentgraf H, von Deimling A.
Leukemia Research. 2010 34(8):1091 - 1093

2009

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel M, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R, Pietsch T, Wiestler O, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
Journal of Clinical Oncology. 2009 27(35):5874-5880


Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach J, Schramm J, Westphal M, Schackert G, Simon M, Tonn J, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.
Journal of Clinical Oncology. 2009 27(34):5743-5750


Post mortem findings in glioblastoma patients treated with thermotherapy using magnetic nanoparticles.
van Landeghem F, Meier-Hauff K, Jordan A, Hoffmann K, Gneveckow U, Scholz R, Thiesen B, Bruck W, von Deimling A.
Biomaterials. 2009 30(1):52-57


Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II.
Stockhammer F, von Deimling A, van Landeghem F.
Histopathology. 2009 54(241-247


Quercetin sensitizes malignant glioma cells to TRAIL induced apoptosis by downregulation of XIAP and survivin.
Siegelin M, Reuss D, Habel A, Rami A, von Deimling A.
Neuro-Oncology. 2009 11(2):122-132


Intraoperative radiofrequency ablation of lung metastases and histological evaluation.
Schneider T, Warth A, Herpel E, Schnabel P, von Deimling A, Eberhard R, Herth F, Dienemann H, Hoffmann H.
Ann Thorac Surg. 2009 87(2):379-384


Novel oncogene amplifications in tumors from a family with Li-Fraumeni-like syndrome.
Rieber J, Remke M, Hartmann C, Korshunov A, Burkhardt B, Sturm D, Mechtersheimer G, Wittmann A, Greil J, Blattmann C, Witt O, Behnisch W, Halatsch M, Orakcioglu B, von Deimling A, Lichter P, Kulozik A, Pfister S.
Genes Chromosomes Cancer. 2009 48(7):558-568


Reuss D, von Deimling A: Gliomas. Edited by von Deimling A. Heidelberg, Springer, 2009, p. pp. 83-102
Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes.
Pfister S, Remke M, Castoldi M, Bai A, Muckenthaler M, Kulozik A, von Deimling A, Pscherer A, Lichter P, Korshunov A.
Acta Neuropathologica. 2009 117(457-464


Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A.
Journal of Clinical Oncology. 2009 27(10):1627-1636


Histology and molecular pathology of pediatric brain tumors.
Pfister S, Hartmann C, Korshunov A.
J Child Neurol. 2009 24(11):1375-1386


Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I, Deubzer H, Wegener D, Pickert D, Linke J-P, Hero B, Kopp-Schneider A, Westermann F, Ulrich S, von Deimling A, Fischer M, Witt O.
Clinical Cancer Research. 2009 15(1):91-99


Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array.
Nord H, Hartmann C, Andersson R, Menzel U, Pfeifer S, Piotrowski A, Bogdan A, Kloc W, Sandgren J, Olofsson T, Hesselager G, Blomquist E, Komorowski J, von Deimling A, Bruder C, Dumanski J, Diaz de Stahl T.
Neuro-Oncology. 2009 11(6):803-818


Mueller W, von Deimling A: Gliomas. Edited by von Deimling A. Heidelberg, Springer, 2009, p. pp. 217-239
Stepwise accumulation of distinct genomic alterations in a patient with progressively metastasizing ependymoma.
Milde T, Pfister S, Korshunov A, Deubzer H, Oehme I, Ernst A, Starzinski-Powitz A, Seitz A, Lichter P, von Deimling A, Witt O.
Genes, Chromosomes Cancer. 2009 48(3):229-238


Reversal of P-glycoprotein-mediated multi-drug resistance by the MDM2 antagonist nutlin-3.
Michaelis M, Rothweiler F, Klassert D, von Deimling A, Doerr H, Cinatl Jr J.
Cancer Research. 2009 69(2):416-421


Somatic mitochondrial mutations in pilocytic astrocytoma.
Lueth M, Wronski L, Giese A, Kirschner-Schwabe R, Pietsch T, von Deimling A, Henze G, Kurtz A, Hernáiz Driever P.
Cancer Genetics and Cytogenetics. 2009 192(1):30-35


RASSF1A, BLU, NORE1A, PTEN and MGMT Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of de novo DNMTs.
Lorente A, Mueller W, Urdangarín E, Lazcoz P, Lass U, von Deimling A, Castresana J.
Brain Pathology. 2009 19(279-292


Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A, Meyer J, Capper D, Christians A, Remke A, Witt H, Pfister S, von Deimling A, Hartmann C.
Acta Neuropathologica. 2009 118(3):401-405


Hartmann C, von Deimling A: Gliomas. Edited by von Deimling A. Heidelberg, Springer, 2009, p. pp. 25-49
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1010 diffuse gliomas.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P, Reifenberger G, von Deimling A.
Acta Neuropathologica. 2009 118(4):469-474


The Arabidopsis thaliana F-box protein FBL17 is essential for progression through the second mitosis during pollen development.
Gusti A, Baumberger N, Nowack M, Pusch S, Eisler H, Potuschak T, De Veylder L, Schnittger A, Genschik P.
PLoS One. 2009 4(3):e4780


Comparison of automated silver enhanced in situ hybridization (SISH) and fluorescence in situ hybridization (FISH) for evaluation of epidermal growth factor receptor (EGFR) status in human glioblastoma.
Gaiser T, Waha A, Moessler F, Bruckner T, Pietsch T, von Deimling A.
Modern Pathology. 2009 22(9):1263-1271


p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas.
Gaiser T, Becker MR, Meyer J, Habel A, Siegelin MD.
Neurochemistry international. 2009 54(7):458-463


Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival.
Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, Reifenberger G, Lichter P, Herold-Mende C, Radlwimmer B.
Clinical Cancer Research. 2009 15(21):6541-6550


Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A, Siegelin M, Steinmüller A, von Deimling A, Lass U, Korn B, Mueller W.
Clinical Cancer Research. 2009 15(17):5457-5465


Control of cell proliferation, organ growth, and DNA damage response operate independently of dephosphorylation of the Arabidopsis Cdk1 homolog CDKA;1.
Dissmeyer N, Weimer AK, Pusch S, De Schutter K, Kamei CL, Nowack MK, Novak B, Duan GL, Zhu YG, De Veylder L, Schnittger A.
Plant Cell. 2009 21(11):3641-3654


Monoclonal Antibody Specific for IDH1 R132H Mutation.
Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A.
Acta Neuropathologica. 2009 118(5):599-601


Stem-cell like glioma cells are resistant to TRAIL/Apo2L and exhibit downregulation of caspase-8 by promoter methylation.
Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, von Deimling A, Siegelin M.
Acta Neuropathologica. 2009 117(4):445-456


Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients.
Ahmadi R, Dictus C, Hartmann C, Zurn O, Edler L, Hartmann M, Combs S, Herold-Mende C, Wirtz CR, Unterberg A.
Acta Neurochirurgica. 2009 151(11):1359-1365

2008

The flavonoid Kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis.
Siegelin M, Reuss D, Habel A, Herold-Mende C, von Deimling A.
Molecular Cancer Therapeutics. 2008 7(11):3566-3574


BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.
Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P.
J Clin Invest. 2008 118(5):1739-1749


Fast detection of MYCN copy number alterations in brain neuronal tumors by real-time PCR.
Malakho SG, Korshunov A, Stroganova AM, Poltaraus AB.
J Clin Lab Anal. 2008 22(2):123-130


Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR.
Lorente A, Mueller W, Urdangarin W, Lázcoz P, von Deimling A, Castresana J.
BMC Cancer. 2008 8(61):

The nuclear receptor tailless is required for neurogenesis in the adult subventricular zone.
Liu HK, Belz T, Bock D, Takacs A, Wu H, Lichter P, Chai M, Schutz G.
Genes Dev. 2008 22(18):2473-2478


Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S.
Acta Neuropathologica. 2008 116(383-390):383-390


Yes and PI3K bind CD95 to signal invasion of glioblastoma.
Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Gröne H-J, Ganten T, Sültmann H, Tüttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A.
Cancer Cell. 2008 13(3):235-248


EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
Holtkamp N, Malzer E, Zietsch J, Okuducu A, Mucha J, Mawrin C, Mautner V-F, Schildhaus H-U, von Deimling A.
Neuro-Oncology. 2008 10(6):946-957


Die neue WHO-Hirntumor-Klassifikation aus dem Jahr 2007.
Hartmann C, Wiestler OD.
Brainstorm. 2008 1(22-25


TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin.
Gaiser T, Becker MR, Habel A, Reuss DE, Ehemann V, Rami A, Siegelin MD.
Neuroscience letters. 2008 442(2):109-113


Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.
Acta Neuropathologica. 2008 116(6):597-602

2007

Molecular genetics of meningiomas: from basic research to potential clinical applications.
Simon M, Bostrom JP, Hartmann C.
Neurosurgery. 2007 60(5):787-798; discussion 787-798


Hypoxic encephalopathy in clinically suspected herpes encephalitis: value of MRI imaging.
Siebert E, Endres M, Hartmann C, Klingebiel R.
Rofo. 2007 179(7):748-750


Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas.
Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F, Wittmann A, Devens F, von Hoff K, Rutkowski S, Kulozik A, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A.
Genes Chromosomes Cancer. 2007 46(9):839-851


Fetal MRI demonstrates glioependymal cyst in a case of sonographic unilateral ventriculomegaly.
Muhler MR, Hartmann C, Werner W, Meyer O, Bollmann R, Klingebiel R.
Pediatr Radiol. 2007 37(4):391-395


Gains at the 1p36 chromosomal region are associated with symptomatic leptomeningeal dissemination of supratentorial glioblastomas.
Korshunov A, Sycheva R, Golanov A, Pronin I.
Am J Clin Pathol. 2007 127(4):585-590


Recurrent cytogenetic aberrations in central neurocytomas and their biological relevance.
Korshunov A, Sycheva R, Golanov A.
Acta Neuropathologica. 2007 113(3):303-312


Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region.
Korshunov A, Cherekaev V, Bekyashev A, Sycheva R.
J Neurooncol. 2007 81(2):131-137


Rapidly progressive paraplegia due to an extradural lumbar meningocele mimicking a cyst. Case report.
Fiss I, Danne M, Hartmann C, Brock M, Stendel R.
J Neurosurg. 2007 7(1):75-79


Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells.
Elstner A, Holtkamp N, von Deimling A.
Clin Exp Metastas. 2007 24(1):57-66

nach oben